GrowGeneration Corp. Q2 2026 Earnings Call Summary

GrowGeneration Corp. reported a third straight quarter of YoY revenue growth, citing a shift to a commercial B2B platform and proprietary brands. Proprietary brand penetration reached 40% ahead of schedule. The company cut store and operating expenses 22% YoY and raised full-year 2026 adjusted EBITDA guidance to $2M-$3M, aided by expected Q3 IEPA tariff refunds. It repurchased 700,000 shares at $1.38.

Original reporting
Published Aug 13, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 1:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
GrowGeneration Corp. Q2 2026 Earnings Call Summary — source image
Decision brief

The 30-second read

$GRWGBullishMed
01

Why it matters

Traders can update 2026 EBITDA expectations based on the raised guidance range and assess near-term risk around Q3 revenue softness and the timing/recognition of IEPA tariff refunds.

02

Market read

Raised full-year 2026 adjusted EBITDA guidance to $2M to $3M, with Q3 revenue guidance of $44M to $46M and an IEPA tariff refund expected in Q3.

03

What to watch

Transportation costs are flagged as a headwind to gross profit dollars in the Storage Solutions segment, which could offset margin gains if volumes or costs move against management’s assumptions.

Relevance 8/10Novelty 7/10Timing: today’s earnings call guidance update for Q3 and full-year 2026

Background

The article summarizes GrowGeneration’s Q2 2026 earnings call, emphasizing a commercial B2B platform shift, proprietary brand penetration, cost reductions, and IEPA tariff refund assumptions.

Company-level read

Ticker impact

$GRWGBullishMedium confidence
Context

GrowGeneration raised full-year 2026 adjusted EBITDA guidance to $2M to $3M and cited expected IEPA tariff refunds in Q3.

Expected impact

Near-term bias higher as traders reprice 2026 EBITDA expectations and the probability/timing of IEPA refund recognition.

Evidence & confidence

The article provides specific, time-bound guidance changes (full-year EBITDA range, Q3 revenue range) plus a concrete driver (IEPA tariff refunds) and a margin mix shift, which are direct inputs to valuation and near-term positioning.

Market effects

Signals continued shift in cultivation-adjacent retail toward B2B recurring consumables and proprietary brands, which may influence read-across for peers’ margin narratives.

No clear regional-specific impact described.

Primarily US-focused (IEPA tariff refunds) with limited global spillover mentioned.

Counterpoint

The Q3 revenue guide is down year-over-year, so the EBITDA beat may be more dependent on tariff refund timing than on underlying demand strength.

Key entities

  • GrowGeneration Corp.

    Subject of the earnings call summary, providing raised 2026 adjusted EBITDA guidance, Q3 revenue guidance, and a share repurchase detail.

Related articles

$GRWGMedAI 8/10

GrowGeneration Beats on Q2 Earnings, Hikes '26 Adjusted EBITDA View

GrowGeneration Corp. (GRWG) reported Q2 2026 results: a 3-cent per-share loss, narrower than the Zacks Consensus estimate of a 4-cent loss and versus an 8-cent loss a year earlier. Sales rose 5.5% to $43.2M. Adjusted EBITDA was $0.3M. The company raised full-year adjusted EBITDA guidance to $2–$3M and reaffirmed sales guidance of $162–$168M.

$GRWGMedAI 8/10

GrowGeneration (GRWG) Q2 2026 Earnings Call Transcript

GrowGeneration (GRWG) reported Q2 2026 revenue of $43.2 million, up 5.5% year over year, with adjusted EBITDA of $0.3 million versus a $1.3 million loss a year earlier. Net loss narrowed to $2.0 million. Gross margin rose to 28.5%. Full-year 2026 guidance: revenue $162-$168 million and adjusted EBITDA $2-$3 million. Cash was $41 million with no debt.

$MRCYMed

Mercury Systems 3Q 2026: Revenue $253.15M, EPS $0.21 — 10-Q Summary

Mercury Systems reported 3Q 2026 revenue of $253.15M, up 12.4% YoY, and net income of $13.09M, reversing a prior-year loss. Growth in radar and electronic warfare applications drove results, while C4I revenue declined. Gross margin improved to 35.2% from 27.9%. The company expects to recognize 46% of its $1.193B remaining performance obligations as revenue in the next 12 months.

$SNWVMed

Sanuwave Announces Q3 FY2026 Financial Results

SANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanuwave Announces Q3 FY2026 Financial Results Q3 2026 revenues were $8.6 million, down 24% from $11.3 million in Q3 2025. Q3 2026 gross margin was 77.3%, versus 77.6% in Q3 2025. GAAP operating loss was $1.1 million for Q3 2026 versus operating income of $0.9 millio

$CPIXHighAI 8/10

CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE

CUMBERLAND PHARMACEUTICALS INC (CPIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE $100 million Strategic Transaction Closed Plans to Submit New Drug Application for Ifetroban in DMD Top-Line Results Announced for Systemic Sclerosis Trial NASHVILLE, Tenn. (Nov. 10, 2026) – Cumberland

$ATROHighAI 8/10

Astronics shares tumble on soft fourth quarter revenue outlook

Astronics (ATRO) reported Q3 earnings of $1.08 per share, beating estimates, with revenue up 28.5% YoY to $271.7M. However, shares fell 11% on Q4 revenue guidance of $255M-$275M, below expectations. The company maintained its full-year 2026 revenue guidance. Aerospace segment sales hit a record $245.5M, with strong demand in inflight entertainment and connectivity.